Cargando…

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

OBJECTIVE: To investigate how often target renin is pursued and achieved in patients with primary aldosteronism (PA) and other low renin hypertension (LRH) treated with mineralocorticoid receptor antagonists (MRAs), as reversal of renin suppression was shown to circumvent the enhanced cardiovascular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tezuka, Yuta, Turcu, Adina F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033169/ https://www.ncbi.nlm.nih.gov/pubmed/33841329 http://dx.doi.org/10.3389/fendo.2021.625457

Ejemplares similares

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2020)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
por: Gorini, Stefania, et al.
Publicado: (2019)

OR20-2 Bilateral Primary Aldosteronism Is Not Excluded by High Adrenal Vein Sampling Lateralization Indices
por: Giordano, Thomas, et al.
Publicado: (2022)

Aldosterone-Regulating Receptors and Aldosterone-Driver Somatic Mutations
por: Lim, Jung Soo, et al.
Publicado: (2021)

The Impact of ACTH on Peripheral Steroids Differs between Unilateral and Bilateral Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Rates of Primary Aldosteronism Screening Among High-Risk Populations
por: Grigoryan, Seda, et al.
Publicado: (2021)

SAT-067 Insights into Paradoxical Bilateral Aldosterone Suppression in the Adrenal Veins of Patients with Primary Aldosteronism
por: Wannachalee, Taweesak, et al.
Publicado: (2019)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
por: Mai, Xurong, et al.
Publicado: (2022)

FRI123 Development And Impact Of A Best Practice Alert For Primary Aldosteronism Screening
por: Charoensri, Suranut, et al.
Publicado: (2023)

Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
por: Lin, Yu-Fang, et al.
Publicado: (2020)

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
por: Tezuka, Yuta, et al.
Publicado: (2022)

SAT-LB90 Angiotensin II and ACTH Receptor Expression in Aldosterone-Producing Adenomas
por: Lim, Jung Soo, et al.
Publicado: (2020)

SAT-061 Determinants of Cosyntropin Effect on Adrenal Vein Sampling Lateralization in Primary Aldosteronism
por: Wannachalee, Taweesak, et al.
Publicado: (2019)

THU597 Po(2)-guided Adrenal Vein Sampling In Primary Aldosteronism
por: Omata, Kei, et al.
Publicado: (2023)

OR02-04 Peripheral Blood Steroid Profiling Discriminates Aldosterone-producing Adenoma Genotypes From Bilateral Primary Aldosteronism
por: Turcu, Adina F, et al.
Publicado: (2023)

Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
por: Funder, John W.
Publicado: (2017)

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
por: Oka, Tatsufumi, et al.
Publicado: (2022)

A Podcast Discussing Aldosterone and Mineralocorticoid Receptor Antagonists in 2021: A Paradigm Shift
por: Epstein, Murray
Publicado: (2022)

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
por: Muñoz-Durango, N., et al.
Publicado: (2015)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

FRI122 Determinants Of Primary Aldosteronism Screening In The US: A Nationwide Physician Survey Study
por: Turcu, Adina F, et al.
Publicado: (2023)

Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke
por: Dinh, Quynh N, et al.
Publicado: (2012)

Renin-Angiotensin-Aldosterone System Inhibition and Mineralocorticoid Receptor Antagonists: The Overriding Importance of Enablers and Dampers
por: Epstein, Murray
Publicado: (2021)

SAT-065 Adrenal Vein Sampling Without Discontinuation Of Mineralocorticoid-Receptor Antagonist Therapy
por: Ganesh, Malini, et al.
Publicado: (2019)

Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy
por: Liao, Che-Wei, et al.
Publicado: (2023)

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

LBODP028 Identifying Biomarkers For Predicting Response To Mineralocorticoid Receptor Antagonist Treatment In Heart Failure
por: Karthigan, Nikshay, et al.
Publicado: (2022)

Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis
por: Moss, Mary E., et al.
Publicado: (2015)

OR04-3 Lysine-Specific Demethylase-1 (LSD1) Deficiency Increases Aldosterone Signaling via Mineralocorticoid Receptor Activation
por: Treesaranuwattana, Thitinan, et al.
Publicado: (2019)

Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
por: Cannavo, Alessandro, et al.
Publicado: (2018)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

SAT-058 Histopathological Analysis of Kidneys and Adrenal Glands in the Same Primary Aldosteronism (PA) Patients: Exploring the Mechanisms of Aldosterone Specific Renal Injuries
por: Ogata, Hiroko, et al.
Publicado: (2019)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

PSUN53 Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low-Renin Hypertension
por: Mansur, Arian, et al.
Publicado: (2022)

The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension
por: Shibata, Shigeru, et al.
Publicado: (2011)

The Glucocorticoid Receptor is Required for Efficient Aldosterone-Induced Transcription by the Mineralocorticoid Receptor.
por: Johnson, Thomas A., et al.
Publicado: (2023)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_84mr9kap2ldscnornpqkgde8jb